Key points for decision makers {#FPar1}
==============================

There are considerable discrepancies regarding the current utilization patterns of anti-cancer medicines in Kosovo as there was no utilization of some anti-cancer medicines considered vital, essential, or necessary based on the essential medicine list.Only a few anti-cancer medicines have very high expenditure; however, there are variations in their use across the years.The MoH should carefully consider introducing updated processes for the selection and pricing for new medicines.

Introduction {#Sec1}
============

For many years health authorities across the world have published annual medicine consumption data, which have been widely used among key stakeholder groups. This includes monitoring the influence of ongoing reforms and initiatives, and using the outputs to plan future initiatives and budgets \[[@CR1]--[@CR4]\]. This is particularly the case in a number of European countries where health authorities and health insurance agencies strive towards universal access within finite budgets.

In Kosovo currently, the Ministry of Health (MoH) leads and organizes health policy processes, achieving many of its objectives through subordinate institutions such as the Kosovo Medicines Agency (KMA). The KMA is responsible for the public health of the population by ensuring drug safety, quality, and efficacy, as well as overseeing the importation of medicines into Kosovo and conducting analyses of overall drug consumption.

New anti-cancer medicines are typically seen as a special group of medicines as this is an emotive area, generally leading to greater leeway for pricing considerations and funding than for other medicines, such as those for cardiovascular diseases or mental health \[[@CR5], [@CR6]\]. There is growing concern worldwide regarding these drugs, with prices of cancer medicines rising up to tenfold during the past 10 years in some countries despite often limited health gains \[[@CR7], [@CR8]\]. This causes particular concern in countries with fixed budgets, with the resultant opportunity cost implications for patients with cancer and other diseases \[[@CR9], [@CR10]\] leading to prescribing restrictions and other measures to limit their use and reduce the prices of new cancer medicines \[[@CR11], [@CR12]\]. Consequently, in European countries with appreciable pressure on resources such as Kosovo, there is an imperative need to review current utilization and expenditure patterns for cancer medicines, as well as the selection process for new anti-cancer medicines, to make sure available resources are being optimally used. In recent years the prevalence of cancers in Kosovo has been increasing \[[@CR13]\]. In 2015, the greatest incidence was for melanomas and other malignant neoplasms of the skin (411 new cases), breast neoplasms (274 new cases), malignant tumors of the digestive system (262 new cases), and malignant tumors of the genital organs (257 new cases). Together, these made up 1204 of the total 1751 new cases of cancer in Kosovo 2015 \[[@CR14]\].

In addition, reports following MoH workshops have suggested that in 2017 there is an increasing trend in the total number of cancers in Kosovo, and that some of these cases are due to better diagnostics and awareness campaigns leading to more patients being diagnosed earlier (A. Jakupi, unpublished data).

The Kosovo University Clinical Center Service (KUCCS) is a key institution in Kosovo's health system as all of the hospitals that offer secondary and tertiary-level care, such as the University Clinical Centre of Kosovo (UCCK), function within its framework. The Oncology Institute operates within the UCCK and KUCCS framework and, along with other institutes, also deals with the overall management of cancer patients in Kosovo, including chemotherapy and radiotherapy. The supply of medicines in UCCK is undertaken through the central pharmacy, which supplies all clinics.

However, little is known generally about medicine consumption in Kosovo including anti-cancer medicines, although drug consumption data for 2011--2013 were published by the KMA in 2014. In addition, the procurement process of the MoH is now centralized, as recommended by the World Health Organization (WHO) and the World Bank \[[@CR15]\]. In contrast, the other processes have been decentralized since 2015 as every hospital, through its own structures, is now responsible for the planning, selection, and ordering of medicines and equipment.

The current selection process to update the oncology medicine list begins with physicians, in this case those in the Institute of Oncology. The list and suggested changes are subsequently reviewed by the head of the clinic, the central pharmacy director, and the general director of the hospital. After this process, the suggested updated list is submitted to the professional working group of the MoH for the final review and approval by the Minister of Health. Figure [1](#Fig1){ref-type="fig"} illustrates this process.Fig. 1Selection process for updating the Essential Medicines List for new anti-cancer medicines (based on Quick et al. \[[@CR16]\])

Once the list is signed by the Minister, the second part of the drug management process proceeds, i.e., the procurement of the medicines from the agreed essential medicines list intended for hospital use. This process is carried out in a centralized way by the MoH for all hospitals in Kosovo, with the system being transparent to help reduce possible corruption \[[@CR17]\]. After this, the process is continued with the distribution to the central pharmacies (of each hospital), from where available medicines are supplied to all of the clinics. This process is carried out under the supervision of the chief pharmacists of the hospitals, ready for clinicians to use the oncology medicines in their clinics.

Consequently, the aim of this paper is to critically review the utilization of and expenditure on anti-cancer medicines in Kosovo, including the selection processes for listing medicines in Kosovo. The findings are then used to suggest future strategies in Kosovo to improve the use of cancer medicines within available resources, building on the expertise of the co-authors working with health authorities across Europe, including Kosovo and wider, and their networks.

Methodology {#Sec2}
===========

The drug utilization and expenditure data were obtained from the MoH and the wholesale drug suppliers, similar to those for other disease areas \[[@CR18]\]. Due to the lack of electronic reporting systems currently in Kosovo, unlike in the Nordic countries and Scotland as well as other central and eastern European countries \[[@CR19]--[@CR25]\], these data have to be manually recorded. Kosovo's pharmaceutical sector has two main parts: the private sector where drug dispensing for ambulatory care patients is achieved through the 621 pharmacies in the country \[[@CR26]\]; and the public sector, which includes hospitals supplied with medicines from the Essential Medicines List, previously procured through the central procurement of the MoH---these medicines are provided only to hospitalized patients.

The utilization of anti-cancer drugs in Kosovo is based on 58 molecules currently available in the Essential Medicine List (EML) according to their generic name or International Nonproprietary Name (INN) \[[@CR27]\] each calendar year. For this initial study, data were collected from wholesalers for the 2011--2013 period \[[@CR28]\], as all of the licensed wholesalers in Kosovo are obliged to make an application to the KMA for all medicines they import, which includes their INN name, brand (originator) name, dosage form, strength, serial number, and quantity. The reason for the 3-year period was that this was the first official publication by the KMA on drug consumption in Kosovo, providing a basis for future reporting \[[@CR29]\]. The methodology is based on the Anatomical Therapeutic Chemical (ATC) drug classification methodology, which is internationally recognized as the standard for undertaking drug utilization research \[[@CR30]--[@CR34]\]. Datasets recorded including the dose, strength, unit quantity, per unit, and overall expenditure for each anti-cancer medicine. Pricing data came from the MoH \[[@CR29]\]. Expenditure was recorded in euros as this is the official currency in Kosovo.

Other sources of drug consumption data include the hospital selection and planning of the medicines process, with data collected from the working group in the MoH \[Ministers decision 60/13 (16 April 2013) and 74/13 (5 June 2013)\]. This group has the duty of categorizing the various medicines, including cancer medicines, into VEN (Vital, Essential, Necessary) categories as per WHO recommendations \[[@CR35]\]; one of the authors (AJ) is a consultant to the MoH leading the group for this type of analysis. The data were further analyzed and interpreted for this publication. The data were collected in Microsoft Excel^®^ (Microsoft Corp., Redmond, WA, USA) and subsequently converted into informative figures and tables.

The analysis of oncology medicines is based on the essential list of cancer medicines approved by the MoH (which is also public). The list of medicines is broken down by overall expenditure during the study period and then by overall class and year before concentrating on the anti-cancer medicines with the highest expenditures. Anti-cancer medicines are classified by VEN as per the MoH working group. This is similar to the VEN analysis and ABC analysis (typically Class A medicines include 10--20% of the items under consideration but constitute 75--80% of total expenditure, Class B constitutes 10--20% of the items under consideration but 15--20% of total expenditure, and Class C constitutes the remaining items but only 5--10% of total expenditure) methodology of the WHO \[[@CR16], [@CR35], [@CR36]\]. The analysis of the 15 anti-cancer medicines with the highest expenditures uses different time periods in view of the appreciable variation that can occur across the years.

In accordance with the WHO ATC classification system, the active substances were divided into different groups in relation to the organ or system on which they act and their therapeutic, pharmacological, and chemical properties \[[@CR30], [@CR37]\]. Medicines are classified into groups at five different levels, including 14 main groups (first level), and further divided into different pharmacological/therapeutic subgroups (second level). The third and fourth levels are the chemical/pharmacological/therapeutic subgroups and the fifth level is the chemical substance. Analysis of medicines according to their ATC classification is used for comparative purposes across countries \[[@CR38]\], provides an overview, and shows trends in medicine utilization in relation to the different therapeutic areas.

Results {#Sec3}
=======

In this analysis, according to the ATC Level 3, the L01X subgroup (other neoplastic agents) of cancer medicines has the greatest expenditure and they are also utilized more than other anti-cancer medicine groups, followed by the L03A group (immunostimulants) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Expenditure on anti-cancer medicines in Kosovo 2011--2013. *L01A* alkylating medicines, *L01B* antimetabolites, *L01C* plant alkaloids and other natural products, *L01D* cytotoxic antibiotics and other related substances, *L01X* other neoplastic agents including cisplatin, carboplatin and rituximab, *L02A* hormones and related substances, *L02B* hormone antagonists and other related substances, *L03A* immunostimulants, *L04A* immunosuppressants, *Y* year(adapted from *Drug Consumption in Kosovo* \[[@CR29]\]) Fig. 3Breakdown of individual anti-cancer medicines by expenditure 2011 to 2013(adapted from *Drug Consumption in Kosovo* \[[@CR29]\])

From Fig. [3](#Fig3){ref-type="fig"}, it can be seen that only a few anti-cancer medicines currently have high expenditures in Kosovo, with expenditure on bevacizumab, rituximab, and the interferons increasing but variable expenditure on trastuzumab. These anti-cancer medicines were chosen for illustrative purposes to demonstrate the appreciable variation in expenditure that can occur between the years, as well as the limited expenditure on certain proven anti-cancer medicines on the list of 58 essential medicines currently available. Analysis of the 15 highest expenditure items (Fig. [4](#Fig4){ref-type="fig"}) gives us further details of key anti-cancer medicines to concentrate on for future analysis. Figure [5](#Fig5){ref-type="fig"} depicts the anti-cancer medicines with the lowest expenditures in recent years, again providing baseline data for future policies and guidelines.Fig. 4Analysis of the 15 anti-cancer drugs annual orders with the highest monetary expenditure including VEN (vital, essential, necessary) analysis between 2011 and 2013 Fig. 5Analysis of the 20 anti-cancer drugs annual orders with the lowest expenditure including VEN (vital, essential, necessary) analysis between 2011 and 2013

Figures [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} show the total expenditure, and the VEN categorization, for the various anti-cancer medicines being utilised in Kosovo. They show that medicines that have a low value per unit (ampoule), such as €2 or €3 per ampoule or similar, did not appear to be ordered by the Oncology Institute, whilst there was a tendency to procure higher-cost medicines. Table [1](#Tab1){ref-type="table"} shows that the final 15 anti-cancer medicines on the Kosovo EML, when sorted by expenditure within a year, have zero orders, whilst the five prior products at the end of the list amounted to €2572 in total---less than the expenditure on two ampoules of the first anti-cancer medicine on the list (Table [1](#Tab1){ref-type="table"}).Table 1Expenditure and VEN (vital, essential, necessary) analyses of anti-cancer medicines in KosovoNo.Generic namePharmaceutical formDose and volumeVEN12-month quantityPrice/unit (€)Expenditure (€)1TrastuzumabConcentration per solution per infusion440 mgV13201550.002,046,000.02BevacizumabConcentration per solution per infusion400 mg/16 mLE6400309.001,977,600.003Imatinib mesylateTablet400 mgE12,60098.301,238,580.004RituximabConcentration per solution per infusion500 mgE6001145.00687,000.005CapecitabineTablet500 mgV210,0002.33489,300.006SorafemibTablet200 mgE10,80036.50394,200.007Erythropoetin betaPrefilled syringe30,000 IUV1800165.00297,000.008IbandronateConcentration per solution per infusion6 mgV2160125.00270,000.009PemetrexedPowder concentration per solution500 mgN240990.00237,600.0010GoserelinPrefilled syringe10.8 mgV480302.00144,960.0011DocetaxelConcentration and dilution per solution per infusion40 mg/mL, 2 mLV480023.73113,904.0012FilgrastimSolution per infusion48 MIUV300036.00108,000.0013RituximabConcentration per solution per infusion100 mgE400230.0092,000.0014TemozolamideCapsules250 mgV168050.8685,444.8015PemetrexedPowder concentration per solution100 mgN240220.0052,800.0016CisplatinPowder concentration per injection50 mgV396013.0051,480.0017AnastrazoleTablet1 mgV60,0000.8249,200.0018IbandronateTablet50 mgV73926.0044,352.0019GemcitabinePowder concentration per solution1000 mgV180019.9035,820.0020CarboplatinSolution per infusion10 mg/mL, 45 mLV140024.5034,300.0021Cyproterone acetateTablet50 mgV39,6000.7730,492.0022DoxorubicinPowder concentration per injection50 mgV34808.2028,536.0023OxaliplatinConcentration per solution per infusion100 mgV180015.0027,000.0024GemcitabinePowder concentration per solution200 mgV36006.0021,600.0025Interferon-α-2aPrefilled syringe3 MIU/5 mLN156013.5021,060.0026DacarbazinePowder concentration per solution per infusion200 mgV90022.6620,394.0027FludarabineTablet10 mgE60029.0017,400.0028Bacillus Calmette-GuerinPowder concentration per solution81--100 mgN20070.0014,000.0029DoxorubicinPowder concentration per injection10 mgV28803.008640.0030IfosfamidePowder concentration per injection1 gV42018.907938.0031EtoposideSolution per infusion100 mgV18003.736714.0032ChlorambucilTablet2 mgN60010.006000.00335-FluorouracilSolution per injection50 mg/mL, 10 mLV20002.565120.0034TamoxifenTablet20 mgV48,0000.104656.0035FludarabinePowder concentration per injection50 mgE12030.003600.0036MesnaTablet400 mgV8403.903275.1637VinblastineSolution per injection1 mg/mL, 10 mLV3405.881999.2038HydroxycarbamideCapsules500 mgN10,0000.151500.0039TioguanineTablet40 mgN2002.50500.0040Calcium folinateSolution per injection10 mg/mL, 5 mLV804.20336.0041MethotrexateTablet2.5 mgV15000.13195.0042MethotrexateSolution per injection50 mg/mL, 1 mLV603.19191.4043AsparaginaseSolution per injection10 MIU, 10 mL362.0072.0044BleomycinPowder concentration per infusion15 IUV026.6045CitarabineSolution per injection100 mg/mL, 1 mLN03.5046CyclophosphamidePowder concentration per solution200 mgV02.5947CyclophosphamidePowder concentration per solution1000 mgV05.6948DaunorubicinPowder concentration per injection20 mgN012.23495-FluorouracilSolution per injection50 mg/mL, 5 mLV01.6850IrinotecanConcentration per solution per infusion20 mg/mL, 5 mLV018.00516-MercaptopurineTablet50 mgN01.5052MelphalanTablet2 mgN60053PaclitaxelConcentration per solution per infusion100 mgV016.0054PaclitaxelConcentration per solution per infusion30 mgV06.3055ProcarbazineTablet50 mgN056Sodium clodronateCapsules800 mgN03.9457Sodium clodronateConcentration per solution per infusion60 mg/mL, 5 mLN015.8658VincristineSolution per injection1 mg/mL, 1 mLV08.50*Caps* capsule, *Conc* concentration, *Dil* dilutant, *E* essential, *Inf* infusion, *Inj* injection, *IU* international units, *mg* milligram, *ml* millilitre, *MIU* million international units, *N* necessary, *Plv* pulvis -- powder, *Sol* solution,*Tbl* tablet, *VEN* Vital -- Essential - Necessary, *V* vital

Table [1](#Tab1){ref-type="table"} shows that eight medicines that are categorized as vital, and comprise 13.7% of the essential list of anti-cancer medicines, have not been ordered at all by the competent authority. In addition, there are 15 molecules that have not been ordered at all (from all three categories of V, E, and N) that comprise 25.86% of the total oncology list.

Discussion {#Sec4}
==========

We believe that there are interesting findings from this study that can provide future direction to the authorities in Kosovo. When comparing our findings with Norway, a European country with one of the highest GDPs (gross domestic product) per capita, versus Kosovo, with one of the lowest, differences can be seen. This is especially evident when comparing the L01X subgroup in 2013, which makes up 61.8% of the ATC code L (ATC L) group in Kosovo, while the same subgroup only constitutes 22% of the ATC L group in Norway \[[@CR39]\]. The L04A group (immunosuppressants) comprised 55% of the total expenditure in Norway versus Kosovo where this same subgroup constituted only 2% of the ATC L group in 2013.

The appreciable differences in the relative consumption of anti-cancer medicines between countries may be regarded as being attributable to a lack of available resources in Kosovo or, alternatively, resources being wasted in one country versus another. On the other hand, differences in percentage utilization among specific medicines in an ATC group across similar time periods, such as immunosuppressants, can be considered to be an indication that current treatment patterns need to be further evaluated to optimize care within finite resources. According to Fig. [5](#Fig5){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, paclitaxel, which is included in two dosage forms (30 and 100 mg) in the EML, is shown to have zero orders---a medicine which now has quite a low acquisition cost and significantly lower prices than other anti-cancer medicines currently being used for similiar indications. In the taxanes group, docataxel and paclitaxel have been key components of chemotherapy regimens since the 1990s, and they are usually prescribed after anthracycline-based chemotherapy \[[@CR40]\]. The paper by Webber-Foster et al. \[[@CR40]\] does not specify which taxane is preferred since they are considered to be similar in effectiveness, albeit with differences in adverse effects and costs. More lives could potentially be saved with paclitaxel but with higher costs than docataxel \[[@CR40]\], although this is not universal. The WHO expert committee, for instance, concludes that both taxanes should be available for breast cancer treatment. This is because, at present, their use, based on available evidence, is different according to specific subgroups of patients and concomitant treatments. In addition, there are no cost-effectiveness data currently available for different settings, or for different outcomes, leading to both taxanes currently being included in the latest WHO essential list of medicines \[[@CR41], [@CR42]\]. A representative of the anthracycline group, daunorubicin (ATC L01DB), also has zero orders (Table [1](#Tab1){ref-type="table"}); this is also a cause for concern. Such discrepancues can also be noted for other medicines in Table [1](#Tab1){ref-type="table"}.

The inclusion of cancer medicines in the EML, and their free availability in hospitals, has benefited a great number of patients with cancer, as currently patients have to cover the full cost of medicines in ambulatory care in Kosovo. However, this will only continue if there is good use of existing resources in hospitals to treat patients with cancer through robust processes for pricing, reimbursing, and funding of medicines, along with a robust process for regularly monitoring their use against agreed guidance.

Table [1](#Tab1){ref-type="table"} and Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"} show that only a few anti-cancer medicines have very high expenditure in Kosovo, but there use varies across the years, causing concern regarding the most effective use of limited resources. The significant differences in the ordering of cancer medicines such as bevacizumab, trastuzumab, and capecitabine suggest current processes are not coordinated. In addition, there currently appear to be different protocols for treatment of different indications in Kosovo, causing confusion (A. Jakupi, unpublished data). This has implications for any treatment approach in hospitals in Kosovo. In addition, 13.7% of cancer medicines which were categorized as vital (Table [1](#Tab1){ref-type="table"}) had zero orders, which is a concern as these medicines are regarded as very necessary. Similarly, 15 products from the essential list of anti-cancer medicines (from the three categories of V, E, or N), or 25.86% of these medicines, had zero orders (Fig. [5](#Fig5){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). With closer scrutiny (Table [1](#Tab1){ref-type="table"}), it can be seen that the prices of these products do not surpass €26 per ampoule, whilst medicines costing more than €1000 per ampoule have orders that in total make up the largest expenditures (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).

As a result, we believe that competent authorities nationally and in hospitals should review and update their processes to make the selection and planning process relating to anti-cancer medicines a continuous and robust process that adheres to the regulations for essential medicines and pharmacoeconomic analyses. This is currently not the case even with the new procurement process. In addition, there should be regular monitoring of the use of medicines and the expenditure on them in practice against an agreed single guidance, rather than multiple guidances, to improve future care efficiently, as seen in other countries such as Sweden \[[@CR2], [@CR11], [@CR43]\]. There are serious concerns relating to different guidances from different national and international groups giving conflicting advice \[[@CR44]\] as this is not in the best interest of any key stakeholder group.

Pharmacoeconomic analysis in accordance with Pallis et al. \[[@CR45]\] should help improve decision-making in Kosovo in such a way that would optimize the use of already limited resources dedicated to the treatment of cancer patients. This is essential with limited resources as per the concept of opportunity cost \[[@CR9]\].

We accept that there are a number of limitations to this study. This includes the fact that there is currently no information on the extent to which people are travelling from neighboring countries to Kosovo for treatment. There is also no doubt that available databases contain incomplete information as there is currently considerable reliance on manually recorded information. However, we believe our findings are robust, providing future direction to all key stakeholder groups in Kosovo in this important disease area.

Recommendations {#Sec5}
===============

In view of our findings, we believe that the MoH in Kosovo should take a lead role in updating current regulations regarding that the process of selection of new and existing medicines and including/excluding medicines from the essential list, including active disinvestment, where appropriate. In addition, the MoH should clearly define the use of and need for pharmacoeconomic analyses to aid reimbursement and funding decisions, encourage the use of drug utilization studies to monitor the use of anti-cancer medicines in routine care, as well as update and consolidate treatment protocols into a single source, replacing the current confusion. Regularly monitoring the utilization and expenditure on anti-cancer medicines will highlight if any agreed essential medicines are currently not being used. Key clinicians should be part of any guideline development and monitoring processes in order to enhance their adherence to jointly agreed medicines and their use, which has worked well in other countries \[[@CR46]\]. The MoH should also separately look at its procurement process, including prices for similar medicines in neighboring countries, to again optimize the use of available resources. Pharmacoeconomics, including value-based pricing, should be part of this.

Furthermore, the MoH could also explore the potential of delegating some of its responsibility to a working group, which could include Drug and Therapy Committees, to regularly monitor the prescription and consumption of medicines in high-priority areas such as cancer. In this way, the drug management cycle would be improved as all parts of the chain would be more precisely monitored and performed. The inclusion of electronic systems in the future will further help with such processes. This will form part of future research projects in Kosovo.

Conclusion {#Sec6}
==========

In this article we have shown discrepancies regarding current procedures relating to the utilization of and expenditure on anti-cancer medicines in Kosovo, including no or limited utilization of anti-cancer medicines currently deemed essential. Our findings have been used to make suggestions for improved processes in order to better manage patients with cancer in Kosovo given the limited resources available. These findings will be followed up in the future to help improve the care of these patients despite the likely continued limited resources in Kosovo.
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